Kilpest India is currently trading at Rs. 365.00, up by 6.40 points or 1.78% from its previous closing of Rs. 358.60 on the BSE.
The scrip opened at Rs. 373.00 and has touched a high and low of Rs. 375.90 and Rs. 340.70 respectively. So far 103161 shares were traded on the counter.
The BSE group 'XT' stock of face value Rs. 10 has touched a 52 week high of Rs. 517.00 on 12-Aug-2020 and a 52 week low of Rs. 54.00 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 375.90 and Rs. 306.60 respectively. The current market cap of the company is Rs. 270.29 crore.
The promoters holding in the company stood at 38.19%, while Non-Institutions held 61.81% stake in the company.
Kilpest India’s subsidiary -- 3B Blackbio Biotech India has extended the earlier agreement with UK & Ireland Distributor HS Biolabs Manchestor, to cover the European region. With this increased territory agreement, HS BioLabs will begin selling all TRUPCR CE IVD Kits across select markets in the European region.
Having already displaced a number of global diagnostic suppliers in the UK with TRUPCR, 3B Blackbio expects HS BioLabs to replicate the same success throughout Europe. The kits offer significant advantages to end users by being simple to use, robust, highly sensitive as well as able to work on a wide range of Real-time PCR machines.
Kilpest India is one of India's leading agri-based companies. The Company manufactures, imports, exports, buys, and sells biological compounds derived from plants, animals, micro organisms.
| Company Name | CMP |
|---|---|
| Lenskart Solutions | 534.85 |
| Poly Medicure | 1468.25 |
| Laxmi Denta | 195.10 |
| Nureca Ltd. | 263.80 |
| Hemant Surgical Inds | 297.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: